Lumos Pharma Announces Abstracts Accepted for Presentation a

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic ca...

Related Keywords

Russia , Sweden , Ukraine , Chicago , Illinois , United States , Stockholm , Texas , Erick Hawkins , Peter Clayton , Lumos Pharma , J Clin Endocrinol , Lisa Miller , Andrew Dauber , Nasdaq , Pediatric Endocrine Society , European Congress , Growth Hormone Research Society , International Congress , Lumos Pharma Inc , Pediatric Growth Hormone Deficiency , Endocrine Society , Annual Meeting , Similar Annualized Height Velocity , Moderate Pediatric Growth Hormone Deficiency , Promising Investigational Safety Record , Growth Trials , Growth Hormone , Orphan Drug Designation , Biological Activities , Orally Active Growth Hormone Secretagogue , Proc Natl Acad Sci , Growth Hormone Release , Oral Ghrelin Mimetic , Body Composition , Clinical Outcomes , Healthy Older Adults , Ann Intern Med , Releasing Peptide Mimetic , Insulin Like Growth Factori Axis , Deficient Adults , Private Securities Litigation Reform Act , Middle East , Annual Report , Quarterly Report , Media Contact ,